Targeted neurostimulation ‘can improve quality of life’

Posted Apr 1 2015 in Other treatments

A new study has demonstrated the potential quality of life (QOL) benefits associated with targeted responsive neurostimulation.

The controlled double-blinded trial of responsive neurostimulation in 191 patients with medically resistant focal epilepsy was led by Stanford University, and saw subjects receive either neurostimulation or placebo treatment for four months, before all patients were treated and followed for two years.

According to results published in the medical journal Epilepsy & Behavior, the treatment and placebo groups did not differ at baseline, but QOL improved in both groups at the end of the blinded period and after the two years of follow up.

At two years, 44 per cent of patients reported meaningful improvements in QOL, and 16 per cent reported declines. There were no overall adverse changes in mood or in suicidal tendencies across the study.

Though there were no changes seen related to seizures and antiepileptic drug use, patients with mesial temporal seizure onsets and those with neocortical seizure onsets both experienced improvements in QOL.

The researchers concluded: “Treatment with targeted responsive neurostimulation does not adversely affect QOL or mood and may be associated with improvements in QOL in patients, including those with seizures of either mesial temporal origin or neocortical origin.”

Posted by Anne Brown

Publication abstract:

News categories